In the glucocorticoid-induced osteoporosis rat model, the use of Gastrodin was found to improve osteoporosis status by activating the Nrf2/Keap1 pathway and upregulating the expression of OCN, BMP-2, and RUNX2. The gene discussed is BMP2; the disease is osteoporosis.